SI1786812T1 - Piridin metilen azolidinoni in njihova uporaba kot inhibitorji fosfoinozitida - Google Patents

Piridin metilen azolidinoni in njihova uporaba kot inhibitorji fosfoinozitida

Info

Publication number
SI1786812T1
SI1786812T1 SI200531418T SI200531418T SI1786812T1 SI 1786812 T1 SI1786812 T1 SI 1786812T1 SI 200531418 T SI200531418 T SI 200531418T SI 200531418 T SI200531418 T SI 200531418T SI 1786812 T1 SI1786812 T1 SI 1786812T1
Authority
SI
Slovenia
Prior art keywords
pyridine methylene
diseases
azolidinones
phosphoinositide
inhibitors
Prior art date
Application number
SI200531418T
Other languages
English (en)
Inventor
Thomas Rueckle
Anna Quattropani
Vincent Pomel
Jerome Dorbais
David Covini
Alexander Bischoff
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of SI1786812T1 publication Critical patent/SI1786812T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200531418T 2004-09-03 2005-09-02 Piridin metilen azolidinoni in njihova uporaba kot inhibitorji fosfoinozitida SI1786812T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60737404P 2004-09-03 2004-09-03
EP04104259 2004-09-03
EP05797231A EP1786812B1 (en) 2004-09-03 2005-09-02 Pyridine methylene azolidinones and their use as phosphoinositide inhibitors
PCT/EP2005/054339 WO2006024666A1 (en) 2004-09-03 2005-09-02 Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors

Publications (1)

Publication Number Publication Date
SI1786812T1 true SI1786812T1 (sl) 2011-12-30

Family

ID=35457295

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200531418T SI1786812T1 (sl) 2004-09-03 2005-09-02 Piridin metilen azolidinoni in njihova uporaba kot inhibitorji fosfoinozitida

Country Status (20)

Country Link
US (2) US7842698B2 (sl)
EP (1) EP1786812B1 (sl)
JP (1) JP5209311B2 (sl)
KR (1) KR101229647B1 (sl)
CN (1) CN101052640B (sl)
AT (1) ATE532783T1 (sl)
AU (1) AU2005279156B2 (sl)
BR (1) BRPI0515627A (sl)
CA (1) CA2576765C (sl)
CY (1) CY1112316T1 (sl)
EA (1) EA012178B1 (sl)
HK (1) HK1106773A1 (sl)
HR (1) HRP20110834T1 (sl)
IL (1) IL181415A (sl)
MX (1) MX2007002604A (sl)
NO (1) NO20071605L (sl)
PL (1) PL1786812T3 (sl)
SI (1) SI1786812T1 (sl)
WO (1) WO2006024666A1 (sl)
ZA (1) ZA200701666B (sl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1648452B1 (en) 2003-07-28 2009-07-22 Merck Serono SA 2-imino-4-(thio)oxo-5-polycyclovinylazolines for use as pi3 kinase inhibitors
EP1790342A1 (de) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
JP2009544723A (ja) * 2006-07-24 2009-12-17 スミスクライン・ビーチャム・コーポレイション Ｐｉ３キナーゼ阻害剤としてのチオゾリジンジオン誘導体
JP5507543B2 (ja) * 2008-04-29 2014-05-28 ノバルティス アーゲー アクチビン様受容体キナーゼ（ａｌｋ４またはａｌｋ５）阻害剤としてのイミダゾ−ピリジン誘導体
US20100061982A1 (en) * 2008-09-10 2010-03-11 Wyeth 3-substituted-1h-indole, 3-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
EP2396322B9 (en) * 2009-02-12 2016-09-14 Merck Serono SA 2-Morpholino-pyrido[3,2-d]pyrimidines
CA2782684C (en) * 2009-12-04 2018-09-04 Mustapha Haddach Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
ES2555224T3 (es) * 2009-12-23 2015-12-29 Jasco Pharmaceuticals Llc Inhibidores de aminopirimidina cinasa
WO2012145617A2 (en) * 2011-04-22 2012-10-26 Jasco Pharmaceuticals, LLC Aminopyrimidine kinase inhibitors
KR20140091522A (ko) * 2011-09-15 2014-07-21 타이페이 메디컬 유니이버시티 심부전증 또는 신경 손상을 치료하기 위한 인돌릴 및 인돌리닐 하이드록사메이트의 용도
WO2013051672A1 (ja) * 2011-10-04 2013-04-11 株式会社ヤクルト本社 チアゾリジン誘導体又はその塩を有効成分とする医薬品
BR112014010563B1 (pt) 2011-11-04 2021-01-12 Jasco Pharmaceuticals, LLC compostos inibidores da aminopirimidina quinase
KR101684950B1 (ko) * 2012-07-23 2016-12-12 주식회사유한양행 퓨란-함유 융합 고리 화합물 또는 그의 염 및 이를 포함하는 약학 조성물
CN104870017B (zh) 2012-11-08 2020-08-14 理森制药股份公司 含有PDE4抑制剂和PI3δ或双重PI3δ-γ激酶抑制剂的药物组合物
CN107835814B (zh) * 2015-04-29 2021-07-23 詹森药业有限公司 氮杂苯并咪唑及其作为ampa受体调节剂的用途
AU2016255431B2 (en) 2015-04-29 2020-05-07 Janssen Pharmaceutica Nv Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators
CN107750250B (zh) 2015-04-29 2021-09-07 詹森药业有限公司 吲哚酮化合物及其作为ampa受体调节剂的用途
WO2016176449A1 (en) 2015-04-29 2016-11-03 Janssen Pharmaceutica Nv Benzimidazolone and benzothiazolone compounds and their use as ampa receptor modulators
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
CN106588909B (zh) * 2017-01-06 2019-08-27 广东工业大学 一种喹啉类衍生物的制备及其在抗炎中的应用
CN109575435A (zh) 2017-09-14 2019-04-05 株式会社日化精密科技 聚丙烯树脂组合物、聚丙烯树脂成形体以及聚丙烯树脂成形体的制造方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003255528B2 (en) 2002-07-10 2009-07-16 Merck Serono Sa Azolidinone-vinyl fused-benzene derivatives
JP2006510661A (ja) * 2002-12-06 2006-03-30 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｐｉ３ｋの阻害剤としてのベンズオキサジン−３−オン類及びその誘導体
EP1581529A1 (en) 2002-12-20 2005-10-05 Warner-Lambert Company Benzoxazines and derivatives thereof as inhibitors of pi3ks
US7202363B2 (en) * 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
EP1648452B1 (en) 2003-07-28 2009-07-22 Merck Serono SA 2-imino-4-(thio)oxo-5-polycyclovinylazolines for use as pi3 kinase inhibitors
WO2006009734A1 (en) * 2004-06-17 2006-01-26 Wyeth Gonadotropin releasing hormone receptor antagonists
ZA200702435B (en) 2004-10-12 2008-06-25 Serono Lab PI3 Kinase gamma inhibitors for the treatment of anaemia
EA200800766A1 (ru) 2005-09-07 2008-06-30 Лаборатуар Сероно С.А. Ингибиторы pi3k для лечения эндометриоза
PE20071020A1 (es) * 2006-03-07 2007-12-11 Smithkline Beecham Corp Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa
CN101553492A (zh) * 2006-08-31 2009-10-07 阵列生物制药公司 Raf抑制剂化合物及其使用方法
AU2008274956B2 (en) * 2007-07-12 2014-08-21 University Of South Florida Inhibitors of Akt/PKB with anti-tumor activity
US7932251B2 (en) * 2007-07-16 2011-04-26 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives

Also Published As

Publication number Publication date
ZA200701666B (en) 2008-07-30
IL181415A (en) 2012-09-24
EP1786812B1 (en) 2011-11-09
BRPI0515627A (pt) 2008-07-29
CA2576765C (en) 2013-05-28
KR101229647B1 (ko) 2013-02-05
AU2005279156A1 (en) 2006-03-09
US8058289B2 (en) 2011-11-15
US20110034458A1 (en) 2011-02-10
HRP20110834T1 (hr) 2011-12-31
KR20070053315A (ko) 2007-05-23
NO20071605L (no) 2007-05-31
ATE532783T1 (de) 2011-11-15
AU2005279156B2 (en) 2011-06-02
WO2006024666A1 (en) 2006-03-09
EA200700541A1 (ru) 2007-08-31
JP2008511589A (ja) 2008-04-17
US7842698B2 (en) 2010-11-30
MX2007002604A (es) 2007-04-25
HK1106773A1 (en) 2008-03-20
IL181415A0 (en) 2007-07-04
CA2576765A1 (en) 2006-03-09
CN101052640B (zh) 2011-05-11
EP1786812A1 (en) 2007-05-23
CN101052640A (zh) 2007-10-10
EA012178B1 (ru) 2009-08-28
CY1112316T1 (el) 2015-12-09
PL1786812T3 (pl) 2012-04-30
US20080269227A1 (en) 2008-10-30
JP5209311B2 (ja) 2013-06-12

Similar Documents

Publication Publication Date Title
PL1786812T3 (pl) Pirydynometylenoazolidynony i ich zastosowanie jako inhibitorów fosfoinozytydów
UA83099C2 (en) Thiazole derivatives and use thereof
UA100358C2 (xx) Похідні піразину та їх застосування
UA96735C2 (en) Thiazole derivatives and use thereof
MX2009009031A (es) Compuestos de quinoxalina y uso de los mismos.
UA92489C2 (en) Thiazole derivatives and use thereof
RS115904A (en) Azolidinone-vinyl fused benzene derivatives
MX2020002963A (es) Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 especifica de ubiquitina.
WO2008103277A3 (en) Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
DE502005005652D1 (de) Heterocyclyl-substituierte nonadepsipeptide
UA88314C2 (en) Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors
WO2007000771A3 (en) Fused quinazolinone derivatives and uses thereof
UA92340C2 (en) Substituted pyridine derivatives
SE0200119D0 (sv) Novel compounds